Neurona’s brain stem cell therapy shows early efficacy in epilepsy

Neurona’s stem cell therapy has promising early results in epilepsy, bolstering a growing push to develop cell therapies for neurological disorders.

William Newton June 15 2023

Neurona Therapeutics reported encouraging data from the first two patients dosed with its regenerative stem cell therapy for epilepsy.

One year after receiving a single dose of NRTX-1001, the first patient in a Phase I/II trial (NCT05135091) reported a more than 95% reduction in seizure frequency, meeting the prespecified efficacy endpoint. Meanwhile, a second patient experienced a more than 90% reduction in seizure frequency seven months after their dose.

Both patients have drug-resistant mesial temporal lobe epilepsy (MLTE), and the first patient had experienced an average of 32 seizures per month leading up to the study. Neither subject has reported a serious adverse event.

Though the data is so far limited to just two patients, it adds to the growing hype surrounding stem cell therapies in neurological disorders. Pharma companies are already testing stem cell therapies in Alzheimer’s disease and Parkinson’s disease, and BrainStorm Cell Therapeutics is seeking regulatory approval for its stem cell therapy in amyotrophic lateral sclerosis (ALS).

Neurona’s NRTX-1001 is a regenerative stem cell therapy designed to deliver neural cells that secrete the neurotransmitter gamma-aminobutyric acid (GABA), silencing seizure activity in the epileptic region of the brain. NRTX-1001 is derived from human pluripotent stem cells, which are manufactured in-house by Neurona.

Neurona’s stem cell therapy in epilepsy

San Francisco, California-based Neurona is looking to bolster strong early data by actively recruiting new patients with MLTE. The Phase I/II trial will enroll up to 10 patients in the initial dose-escalation stage and up to 40 patients in total.

Approximately 50 million people globally experience epilepsy, and up to one-third of people do not respond to existing therapies. Though many available epilepsy treatments target seizure symptoms, researchers and patients are pushing for more holistic treatment approaches to the potentially fatal condition.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close